MCRB Long Call Strategy
MCRB (Seres Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015.
MCRB (Seres Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $75.1M, a beta of 0.12 versus the broader market, a 52-week range of 6.53-29.98, average daily share volume of 53K, a public-listing history dating back to 2015, approximately 103 full-time employees. These structural characteristics shape how MCRB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.12 indicates MCRB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long call on MCRB?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current MCRB snapshot
As of May 15, 2026, spot at $7.69, ATM IV 132.70%, IV rank 29.31%, expected move 38.04%. The long call on MCRB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on MCRB specifically: MCRB IV at 132.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a MCRB long call, with a market-implied 1-standard-deviation move of approximately 38.04% (roughly $2.93 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MCRB expiries trade a higher absolute premium for lower per-day decay. Position sizing on MCRB should anchor to the underlying notional of $7.69 per share and to the trader's directional view on MCRB stock.
MCRB long call setup
The MCRB long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MCRB near $7.69, the first option leg uses a $7.69 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MCRB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MCRB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $7.69 | N/A |
MCRB long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
MCRB long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on MCRB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on MCRB
Long calls on MCRB express a bullish thesis with defined risk; traders use them ahead of MCRB catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
MCRB thesis for this long call
The market-implied 1-standard-deviation range for MCRB extends from approximately $4.76 on the downside to $10.62 on the upside. A MCRB long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current MCRB IV rank near 29.31% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on MCRB at 132.70%. As a Healthcare name, MCRB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MCRB-specific events.
MCRB long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MCRB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MCRB alongside the broader basket even when MCRB-specific fundamentals are unchanged. Long-premium structures like a long call on MCRB are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current MCRB chain quotes before placing a trade.
Frequently asked questions
- What is a long call on MCRB?
- A long call on MCRB is the long call strategy applied to MCRB (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With MCRB stock trading near $7.69, the strikes shown on this page are snapped to the nearest listed MCRB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are MCRB long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the MCRB long call priced from the end-of-day chain at a 30-day expiry (ATM IV 132.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a MCRB long call?
- The breakeven for the MCRB long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current MCRB market-implied 1-standard-deviation expected move is approximately 38.04%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on MCRB?
- Long calls on MCRB express a bullish thesis with defined risk; traders use them ahead of MCRB catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current MCRB implied volatility affect this long call?
- MCRB ATM IV is at 132.70% with IV rank near 29.31%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.